Should I buy or sell Immuneering stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IMRX shares. View IMRX analyst ratings or view top-rated stocks .

What is Immuneering's stock price target for 2024?

8 analysts have issued 12 month price targets for Immuneering's shares. Their IMRX share price targets range from $3.00 to $25.00. On average, they predict the company's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 662.7% from the stock's current price. View analysts price targets for IMRX or view top-rated stocks among Wall Street analysts .

How have IMRX shares performed in 2024?

Immuneering's stock was trading at $7.35 on January 1st, 2024. Since then, IMRX shares have decreased by 75.9% and is now trading at $1.77. View the best growth stocks for 2024 here .

Are investors shorting Immuneering?

Immuneering saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,880,000 shares, an increase of 10.3% from the March 15th total of 2,610,000 shares. Based on an average daily trading volume, of 595,100 shares, the short-interest ratio is presently 4.8 days. Currently, 14.0% of the shares of the stock are short sold. View Immuneering's Short Interest .

When is Immuneering's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our IMRX earnings forecast .

How were Immuneering's earnings last quarter?

Immuneering Co. (NASDAQ:IMRX) released its earnings results on Friday, March, 1st. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.06.

What ETF holds Immuneering's stock?

Range Cancer Therapeutics ETF holds 13,232 shares of IMRX stock, representing 1.36% of its portfolio.

When did Immuneering IPO?

Immuneering (IMRX) raised $105 million in an IPO on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO.

How do I buy shares of Immuneering?

Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IMRX

Immuneering (IMRX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free IMRX Stock Alerts

$1.77

-0.09 (-4.84%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.76
▼
$1.89
50-Day Range: $1.84
▼
$6.76
52-Week Range: $1.75
▼
$14.29

Volume: 177,971 shs
Average Volume: 575,190 shs
Market Capitalization: $51.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.50

Get Immuneering alerts:

Immuneering MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 662.7% Upside
$13.50 Price Target
Short Interest: Bearish
13.97% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.31
Based on 7 Articles This Week
Insider Trading: Selling Shares
$3.05 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.89) to ($1.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.74 out of 5 stars

Medical Sector

219th out of 919 stocks

Pharmaceutical Preparations Industry

83rd out of 410 stocks

4.3

Analyst's Opinion

Consensus Rating
Immuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Immuneering has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
13.97% of the float of Immuneering has been sold short.
Short Interest Ratio / Days to Cover
Immuneering has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Immuneering has recently increased by 10.34%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Immuneering does not currently pay a dividend.
Dividend Growth
Immuneering does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMRX.

3.0

News and Social Media Coverage

News Sentiment
Immuneering has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Immuneering this week, compared to 2 articles on an average week.
Search Interest
17 people have searched for IMRX on MarketBeat in the last 30 days. This is an increase of 42% compared to the previous 30 days.
MarketBeat Follows
14 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immuneering insiders have sold 1,045.28% more of their company's stock than they have bought. Specifically, they have bought $266,645.00 in company stock and sold $3,053,819.00 in company stock.
Percentage Held by Insiders
23.00% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Immuneering are expected to grow in the coming year, from ($1.89) to ($1.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immuneering is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immuneering is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immuneering has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Immuneering Stock (NASDAQ:IMRX)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

IMRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMRX Stock News Headlines

April 5, 2024 | insidertrades.com

Cormorant Asset Management, Lp Sells 400,000 Shares of Immuneering Co. (NASDAQ:IMRX) Stock

March 26, 2024 | insidertrades.com

3 Stocks Insiders Are Buying That Analysts Love

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 26, 2024 | insidertrades.com

Immuneering Co. (NASDAQ:IMRX) Insider Harold Eugene Brakewood Buys 3,900 Shares

March 26, 2024 | insidertrades.com

Insider Buying: Immuneering Co. (NASDAQ:IMRX) Director Acquires 25,000 Shares of Stock

March 22, 2024 | insidertrades.com

Insider Buying: Immuneering Co. (NASDAQ:IMRX) Insider Acquires 3,818 Shares of Stock

March 20, 2024 | insidertrades.com

Immuneering Co. (NASDAQ:IMRX) CEO Purchases $55,400.00 in Stock

March 19, 2024 | insidertrades.com

Cormorant Asset Management, Lp Sells 509,091 Shares of Immuneering Co. (NASDAQ:IMRX) Stock

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 17, 2024 | msn.com

Immuneering (IMRX) Price Target Decreased by 11.43% to 13.55

April 16, 2024 | americanbankingnews.com

Immuneering Co. (NASDAQ:IMRX) Short Interest Up 10.3% in March

April 14, 2024 | americanbankingnews.com

Immuneering (NASDAQ:IMRX) Stock Rating Reaffirmed by Needham & Company LLC

April 11, 2024 | investing.com

Immuneering advances pancreatic cancer treatment trial

April 9, 2024 | finanznachrichten.de

Immuneering Corporation: IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

April 9, 2024 | globenewswire.com

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

April 9, 2024 | americanbankingnews.com

Immuneering Co. (NASDAQ:IMRX) Receives Consensus Rating of "Moderate Buy" from Analysts

April 3, 2024 | globenewswire.com

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence

March 27, 2024 | globenewswire.com

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

March 21, 2024 | investing.com

Immuneering CEO acquires $55.3k in company stock

March 21, 2024 | finance.yahoo.com

Immuneering Director Acquires 7.5% More Stock

March 18, 2024 | msn.com

Immuneering stock rebounds 34% following last week's selloff

March 18, 2024 | benzinga.com

Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

March 18, 2024 | msn.com

Canopy Growth, Outlook Therapeutics, Immuneering among healthcare movers

March 15, 2024 | msn.com

U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.49%

March 15, 2024 | markets.businessinsider.com

Immuneering: Hold Rating Amidst Potential and Uncertainties in Drug Efficacy

March 15, 2024 | markets.businessinsider.com

Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data

See More Headlines

Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/01/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IMRX
CUSIP: N/A
CIK: 1790340
Web: www.immuneering.com
Phone: 617-500-8080
Fax: N/A
Employees: 68
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.50
High Stock Price Target: $25.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +631.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-53,470,000.00
Net Margins: N/A
Pretax Margin: -5,163,499.50%
Return on Equity: -52.49%
Return on Assets: -47.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.35
Quick Ratio: 11.35

Sales & Book Value

Annual Sales: $320,000.00
Price / Sales: 168.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.09 per share
Price / Book: 0.60

Miscellaneous

Outstanding Shares: 29,280,000
Free Float: 22,548,000
Market Cap: $54.02 million
Optionable: Not Optionable
Beta: -0.89

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Benjamin J. Zeskind M.B.A. (Age 42)
Ph.D., Co-Founder, President, CEO & Director
Comp: $898.42k
Mr. Robert J. Carpenter M.B.A. (Age 78)
M.S., Co-Founder & Chair Emeritus
Comp: $83.17k
Dr. Brett M. Hall Ph.D. (Age 56)
Chief Scientific Officer
Comp: $867.92k
Ms. Mallory Morales CPA (Age 40)
Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
Ms. Paula George CPA
Director of Accounting & Operations and Assistant Corporate Controller
Mr. Michael D. Bookman J.D. (Age 36)
Chief Legal Officer & Secretary
Ms. Leah R. Neufeld (Age 52)
Chief People Officer
Dr. Peter King Ph.D.
Head of Discovery & VP
Dr. Praveen Nair Ph.D.
Head of Translational Pharmacology & VP
Mr. Harold E. Brakewood (Age 59)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immuneering stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IMRX shares.
View IMRX analyst ratings or view top-rated stocks.
What is Immuneering's stock price target for 2024?: 8 analysts have issued 12 month price targets for Immuneering's shares. Their IMRX share price targets range from $3.00 to $25.00. On average, they predict the company's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 662.7% from the stock's current price.
View analysts price targets for IMRX or view top-rated stocks among Wall Street analysts.
How have IMRX shares performed in 2024?: Immuneering's stock was trading at $7.35 on January 1st, 2024. Since then, IMRX shares have decreased by 75.9% and is now trading at $1.77.
View the best growth stocks for 2024 here.
Are investors shorting Immuneering?: Immuneering saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,880,000 shares, an increase of 10.3% from the March 15th total of 2,610,000 shares. Based on an average daily trading volume, of 595,100 shares, the short-interest ratio is presently 4.8 days. Currently, 14.0% of the shares of the stock are short sold.
View Immuneering's Short Interest.
When is Immuneering's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our IMRX earnings forecast.

How were Immuneering's earnings last quarter?: Immuneering Co. (NASDAQ:IMRX) released its earnings results on Friday, March, 1st. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.06.
What ETF holds Immuneering's stock?: Range Cancer Therapeutics ETF holds 13,232 shares of IMRX stock, representing 1.36% of its portfolio.
When did Immuneering IPO?: Immuneering (IMRX) raised $105 million in an IPO on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO.
How do I buy shares of Immuneering?: Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMRX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immuneering (IMRX) Stock Price, News & Analysis

Immuneering MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Immuneering Stock (NASDAQ:IMRX)

IMRX Stock Price History

IMRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IMRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™